

Part 2 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura XXXXXX
	Attorney Docket No.	3073.004A

U.S. PATENTS

Examiner Initials	Cite No.	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	A					

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials	Cite No.	Publication Number	Kind Code ²	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	B					

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Figures Appear	Translation	
								Yes	No
	C								

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	D1	Essassi et al.: Synthèse et Herocyclisation Des (Pyrazolyl-3-(5))-2 Benzimidazoles en Catalyse Par Transfert de Phase, <i>Bull. Soc. Chim. Belg.</i> Vol. 96, pages 63 - 67, 1987.
	D2	International Search Report for WO 2005/002552 (PCT/GB2004/002824 filed July 5, 2004).
	D3	Blankley et al.: Antihypertensive Activity Of 6-Arylpyrido[2,3-d] Pyrimidin-7-Amine Derivatives. 2. 7-Acyl Amide Analogues, <i>Journal Of Medicinal Chemistry</i> , Vol. 26, No. 3, March 1, 1983, pages 404-411.
	D4	Abd El-Wareth A O Sarhan et al.: Synthesis, Characterization and Reactions of 2-Deoxo-5-Deazaalloxazines, <i>Bioorganic & Medicinal Chemistry</i> , Vol. 9, January 1, 2001, pages 2993-2998.
	D5	Mesguiche et al.: 4-Alkoxy-2,6-Diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2, <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 13, January 1, 2003, pages 217-222.

Part 2 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application No.	10/564,166
	Filing Date:	July 5, 2004
	First Name Inventor	Valerio Berdini
	Art Unit	1626
	Examiner Name	Stockton, Laura [REDACTED]
	Attorney Docket No.	3073.004A

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	D6	GB search report GB 0315657.7 filed July 3, 2003
	D7	GB search report GB 0324919.0 filed October 24, 2003
	D9	European Supplementary Search report EP Application No. 04 743 172.1 9/19/2008
	D9	GB search report GB 0428552.4 filed December 30, 2004
	D10	GB search report GB 0428554.0 filed December 30, 2004
	D11	International Search Report PCT/GB2005/005097 filed December 30, 2005 3/28/2006
	D12	GB search report GB 0526607.7 filed December 30, 2005
	D13	International Search Report PCT/GB2006/004954 filed December 29, 2006 5/14/2007

EXAMINER: /Laura L. Stockton/

Date Considered 11/23/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP Section 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3) ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/